Related Experiment Video
Updated: Jan 12, 2026
Cortical Bone Assessment Using Ultrasonic Guided Waves: A Reproducibility Study in a Healthy Population
Published on: January 31, 2025
Fragile balance: Managing bone health in people with intellectual disability and epilepsy, an english multi-site
Rachel Menon1, Charlotte Young1, Madeline Dale2
1Cornwall Partnership NHS Foundation Trust, Truro, UK.
Background:
People with intellectual disability (ID) experience poorer health outcomes than the general population, with epilepsy and polypharmacy contributing to further risks. Bone health is a neglected area, despite the established association between antiseizure medications (ASMs), (especially those cautioned by the UK Medicines and Healthcare products Regulatory Agency (MHRA)), and reduced bone mineral density. We aimed to evaluate prescribing practices, fracture risk, and bone health management in adults with ID and epilepsy attending specialist ID services.
Methods:
A cross-sectional study was conducted across three English specialist ID epilepsy services between August 2021-August 2022. Data were collected from case-note review, including ASM prescribing, falls and fracture history, bone health monitoring, and protective treatments. Descriptive statistics, Chi-squared and Mann-Whitney U tests were conducted. Logistic regression was used to examine associations between ASM use and fracture risk.
Results:
Of 484 adults analysed almost all (97%) were prescribed ≥1 ASM, with 18% receiving four or more and 63% receiving at least one MHRA-cautioned ASM. Over 25% on MHRA-cautioned ASMs had a history of fractures, yet 38% received no bone-protective treatment. Patients with severe-profound ID were prescribed significantly more ASMs than those with mild-moderate ID. Each additional ASM increased fracture risk by 37%, and each additional MHRA-cautioned ASM by 43%.
Conclusions:
Adults with ID and epilepsy are frequently exposed to polypharmacy, including bone health-compromising ASMs, yet bone health monitoring and treatment remain suboptimal. Targeted strategies and ID-specific guidance are urgently required to reduce fracture risk and improve outcomes in this vulnerable group.
Related Concept Videos
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:31Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients